Reunion Neuroscience

Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.

Reunion Neuroscience headquartered in North America, operates in the Biotechnology, Pharmaceutical, Mental Health sector. The company focuses on Biotechnology and has secured $1.2B in funding across 12 round(s). With a team of 1-10 employees, Reunion Neuroscience is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Reunion Neuroscience, raised $103.0M. Discover more about their projects, partnerships, and impact on our platform.